Picture loading failed.

Anti-CD22 therapeutic antibody (Pre-made Epratuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-190-1mg 1mg 3090
GMP-Bios-ab-190-10mg 10mg 21890
GMP-Bios-ab-190-100mg 100mg 148000
GMP-Bios-ab-190-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD22 therapeutic antibody (Pre-made Epratuzumab biosimilar,Whole mAb)
INN Name Epratuzumab
TargetCD22
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI Structure5vkk:AB:HL/5vl3:EF:AB:HL:CD
95-98% SI StructureNone
Year Proposed1999
Year Recommended2000
CompaniesCharite - Universitatsmedizin Berlin;Children's Oncology Group;Immunomedics;National Cancer Institute (USA);UCB
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedPrecursor cell lymphoblastic leukaemia-lymphoma;Systemic lupus erythematosus;Non-Hodgkin's lymphoma;Cachexia
Development Techna